Men Are Twice as Likely to Die From This Stress-Related Heart Issue
Stress hits everyone. Whether it's the loss of a loved one, a job, or the end of a relationship, dealing with grief is never easy. But for men, the stakes may be even higher. Research shows that men are twice as likely to die from takotsubo cardiomyopathy—a stress-induced heart condition better known as 'broken heart syndrome'—compared to women.
A recent study published in the Journal of the American Heart Association examined nearly 200,000 U.S. adults from 2016 to 2020. Researchers found that although the heart condition was more common among women, the death rate among them was half that of men at 5.5%, compared to 11.2% for men.
'Takotsubo cardiomyopathy is a serious condition with a substantial risk of death and severe complications,' said study author M. Reza Movahed, M.D., Ph.D., an interventional cardiologist and clinical professor of medicine at the University of Arizona's Sarver Heart Center in Tucson, ArizonaTakotsubo cardiomyopathy, aka broken heart syndrome, is a heart condition most often brought on by extreme emotions or stressful situations. While it generally occurs temporarily, people can continue to feel unwell for long periods of time. Symptoms include shortness of breath and chest pain.
During the study period, major complications caused 35.9% of participants to die from congestive heart failure, 20.7% from atrial fibrillation, 6.6% from cardiogenic shock, 5.3% from stroke, and 3.4% from cardiac arrest.
'The health care team needs to carefully review coronary angiograms that show no significant coronary disease with classic appearance of left ventricular motion, suggesting any subtypes of stress-induced cardiomyopathy," Movahed said in a press release. "These patients should be monitored for serious complications and treated promptly."
He also adds that some complications, such as embolic stroke, could be prevented with early detection and treatment.
Movahed added that further research is needed to fully understand the mortality discrepancy between males and females and how to best manage patients with this condition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value 0.005, HR: 0.46 [0.26, 0.80]) observed in 3rd-6th line metastatic pancreatic cancer, correlated with reversal of lymphopenia. Patients with lower tumor burden and improved lymphocyte counts (ALC ≥1,000) had a median overall survival of 10.1 months, supporting earlier intervention in the disease course. CULVER CITY, Calif., June 03, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a well-established root cause of early mortality in patients with cancer across all tumor types, correlates with significant improved survival. While anemia and neutropenia have long been addressed by agents like Epogen and Neupogen, no therapy has ever existed for lymphopenia—until now. ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist approved in April 2024 for BCG-unresponsive non-muscle- invasive bladder cancer carcinoma in situ with or without papillary disease, represents the first lymphocyte-stimulating agent (LSA) capable of expanding lymphocytes critical for immunogenic cell death, such as natural killer (NK) and T cells. These findings emphasize the need for a therapy to overcome treatment induced lymphopenia with higher mortality as presented at ASCO 2025 by several institutions (Abstract #8054, Satoskar et al. and Abstract #2663, Saleh et al.) In a single-arm QUILT-88 clinical trial of 86 participants with third-to-sixth-line metastatic pancreatic cancer with very high tumor burden (CA19-9 levels exceeding 34,000 IU/ml), for which no therapy currently exists, patients received ANKTIVA subcutaneously in combination with off-the-shelf, ex-vivo infusion of CAR-NK cells (PD-L1 t-haNK) and low dose immuno-modulating chemotherapy. This first reported study of treating lymphopenia demonstrated significant differences in median overall survival in subjects whose lymphopenia was reversed (Absolute Lymphocyte Count: ALC ≥ 1,000). In 67 out of 86 subjects, reversal of lymphopenia was achieved and median overall survival was significantly prolonged compared to those who remained in severe lymphopenia with P-value 0.005, HR: 0.46 (0.26, 0.80) in Figure 1. In subjects with lymphopenia rescue and a lower tumor burden (less than the median CA19-9 of 34,000 IU/mL), the median overall survival in these very advanced metastatic pancreatic cancer patients exceeded 10 months (Figure 2). These findings of improved survival in pancreatic cancer patients with lower tumor burden point to the potential of further prolonged overall survival in pancreatic cancer patients if treated in the first line or neoadjuvant stages of disease. Highlighting the importance of lymphopenia reversal, Oncologist published a peer-reviewed paper titled "Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate," demonstrating that in a patient with 2nd line metastatic pancreatic cancer treated with the full Cancer BioShield platform—including ANKTIVA, CAR-NK cells (PD-L1 t-haNK), and antigen-targeting adenoviruses—remained in remission for over six years and maintains a high quality of life at the date of this release. The expanded access authorization announced yesterday enables patients across all solid tumor types who have exhausted first-line therapy including chemotherapy, radiation, or immunotherapy to receive Anktiva as a lymphocyte stimulating agent to protect the immune system from the lymphogenic adverse effects of current standards of care. The ASCO Annual Meeting 2025 materials from ImmunityBio can be found below: Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic Text: Poster PDF: About the Cancer BioShield™ Platform The Cancer BioShield platform is a first-in-class immunotherapy strategy designed to restore immune competence by reversing lymphopenia—the loss of functional immune cells caused by cancer itself and by conventional treatments such as chemotherapy, radiation and immunotherapy. At its core is ANKTIVA® (nogapendekin alfa inbakicept-pmln), an IL-15 agonist approved for BCG-unresponsive non-muscle-invasive bladder cancer CIS with or without papillary disease, activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells, restoring lymphocyte levels critical for immunosurveillance, immunogenic cell death, and long-term tumor control. The platform employs a multi-modal approach: In-vivo stimulation: Subcutaneous administration of ANKTIVA expands NK and T cells, boosting anti-tumor immunity. Ex-vivo targeted cytotoxicity: Off-the-shelf PD-L1 t-haNK CAR-NK cells are engineered to target and eliminate PD-L1–expressing tumor cells and immunosuppressive neutrophils (myeloid-derived suppressor cells), enhancing anti-tumor specificity and reducing immune evasion. Memory Cytokine-Enriched Natural Killer (M-ceNK) cell therapy: M-ceNK cells are developed via cytokine activation and expansion of autologous and allogeneic NK cells collected through apheresis, potentially providing long-term immune memory and sustained cytotoxic capacity. Together, these components offer a comprehensive, novel, immune-restoring therapeutic platform aimed at not only expanding effector immune cells but also overcoming tumor-mediated immune suppression to support long-term disease control. The platform's effectiveness can be tracked through universally utilized, simple complete blood count (CBC): increases in absolute lymphocyte count (ALC) reflect ANKTIVA's lymphocyte-stimulating activity, while reductions in the neutrophil-to-lymphocyte ratio (NLR) demonstrate PD-L1 t-haNK's immunosuppressive neutrophil targeting. Low ALC and high NLR levels are laboratory measurements that have been extensively reported as predictive biomarkers of poor prognosis with early mortality across all tumor types5,6. The data presented by ImmunityBio for the first time demonstrates that improving ALC and NLR correlates with significant enhanced overall survival and clinical benefit. About Lymphopenia and Absolute Lymphocyte Count (ALC) Lymphopenia—the loss of key immune cells such as NK, CD4+, and CD8+ T cells—is a common side effect of chemotherapy1, radiation2,3, and some immunotherapies4. Unlike anemia and neutropenia, which have FDA-approved treatments like EPO and Neupogen, no therapy previously existed to treat this immune cell depletion. Lymphopenia weakens the immune system, increases infection risk, and is linked to early death across many cancer types5. Low Absolute Lymphocyte Count (ALC) is a recognized poor prognostic marker. ANKTIVA® is the first approved therapy to restore lymphocyte levels by activating and expanding NK and T cells—without increasing immunosuppressive T regulatory cells7. More information on lymphopenia could be found on Twitter/X @DrPatSoonShiong articles here: References: Ray-Coquard I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009 Jul 1;69(13):5383-91. doi: 10.1158/ Epub 2009 Jun 23. PMID: 19549917; PMCID: PMC2775079. Chen D, et al. Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):196-203. doi: 10.1016/ Epub 2020 Feb 7. Pike LRG, et al. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151. doi: 10.1016/ Epub 2018 Sep 15. PMID: 30227198. Lee, Y.J., et al. Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. Sci Rep 12, 626 (2022). Ménétrier-Caux C., et al. Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? J Immunother Cancer. 2019 Mar 28;7(1):85. doi: 10.1186/s40425-019-0549-5. PMID: 30922400; PMCID: PMC6437964. Templeton AJ, et al. Prognostic role of neutrophil-to-lymphocyte (NLR) ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124. doi: 10.1093/jnci/dju124. PMID: 24875653. FDA ANKTIVA Label, April 2024 - About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the expectation that the EAP described herein will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iii) risks and uncertainties regarding commercial launch execution, success and timing, (iv) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (v) whether clinical trials will result in registrational pathways and the risks, (vi) whether clinical trial data will be accepted by regulatory agencies, (vii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (viii) potential delays in product availability and regulatory approvals, (ix) ImmunityBio's ability to retain and hire key personnel, (x) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xi) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xiv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. View source version on Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio, Inc. +1 Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Cardiologists are begging you to never practice this mid-morning habit
Are you tired in the mid-morning? Experts advise not to reach for the caffeine. A second or third cup of coffee may not have the effect you hope it will. The stimulant can raise cortisol levels, which naturally dip around 10 or 11 a.m. Cortisol is the body's main stress hormone. It can also regulate inflammation and blood pressure and boost energy. But, high cortisol doesn't necessarily equate to high energy. 'Cortisol can be high and we can feel tired or low energy, like when we wake up. Or it can be low and we can feel high energy like the mid-morning. If I had to equate cortisol levels with something, it would be irritation,' Calm's Dr. Chris Mosunic said in a statement. Regardless, caffeine raises cortisol, 'potentially amplifying sympathetic tone," Dr. Marschall Runge told Parade. "[This] may heighten blood pressure or heart rate more than if caffeine is consumed earlier,' the cardiologist said. The sympathetic nervous system is a network of nerves that helps your body activate its 'fight-or-flight' response. Caffeine can raise sympathetic nerve activity and blood pressure. Previous research has shown people who drink coffee on a regular basis don't see that rise in blood pressure. "Until now we have attributed the cardiovascular effects of coffee to caffeine, but we found non-coffee drinkers given decaffeinated coffee also display these effects," Dr. Roberto Corti, a cardiologist at University Hospital in Zurich, explained in 2002. Some groups are especially vulnerable to mid-morning caffeine, according to Runge. They include people with anxiety disorders, those with a slower caffeine metabolism, women during their period or perimenopause, people with hypertension or prehypertension, individuals with a slow CYP1A2 gene variant, and people with known cardiovascular risks. If any of these groups repeatedly consume a second cup or an empty stomach during this period of day, they could see negative cumulative effects, he warned. "Repeated stimulation might stress the system over time," Runge warned. But, moderate caffeine use 'doesn't increase cardiovascular risk' and there are major benefits to drinking coffee. A recent study found it helped women age better. Between two to four cups of coffee a day should be safe. An eight-ounce cup contains close to 100 milligrams of caffeine. The U.S. Food and Drug Administration recommends no more than 400 milligrams of caffeine daily for adults. Notably, decaffeinated coffees are not caffeine free and everyone responds to caffeine differently. Beyond that — especially on an empty stomach — risks may increase. 'When your cortisol levels stay elevated, you're at an increased risk for weight gain, diabetes, heart problems and other health concerns,' dietitian Anthony DiMarino said. Eat well and regularly. Talk a short walk and make sure to stay hydrated — with water! "Dehydration often mimics fatigue," Runge noted.
Yahoo
an hour ago
- Yahoo
Eating more of these plant-based foods could lower your risk of heart disease and diabetes
Eating more nuts, fruits, vegetables, and whole grains may help to reduce your risk of contracting deadly heart disease and type 2 diabetes. Researchers said this week that people who consumed more phytosterols — a natural compound found in plant foods — significantly delayed both of the conditions. Furthermore, eating more of them was linked to reduced inflammation, markers of better insulin regulation, and differences in the gut microbiome that may contribute to healthy metabolism. The study was not designed to confirm why this is the case, but the researchers said their findings strengthen the evidence. More than 7000,000 Americans die from heart disease and some 101,000 die from diabetes. 'Our findings support the dietary recommendation of adhering to healthy plant-based dietary patterns that are rich in vegetables, fruits, nuts and whole grains,' Dr. Fenglei Wang, a research associate at the Harvard T.H. Chan School of Public Health, said in a statement. 'These findings can help people make informed dietary choices.' Wang presented the observational findings on Tuesday at the flagship annual meeting of the American Society for Nutrition. Some phytosterol-rich foods include corn, almonds, broccoli, bananas, and wheat bread. Previous research had found that eating foods with phytosterols can help to improve peoples' health by lowering bad cholesterol, and may reduce the risk of cancer. However, most clinical trials have used high doses of the phytosterols that were beyond what someone might get through just their own diet. The new research is the first to show the benefits as part of a normal diet. To reach these conclusions, Wang and his colleagues looked at data from more than 200,000 American adults that were a part of three studies. All of the participants were nurses or other health professionals and nearly 80 percent were women. Over the course of 36 years, more than 20,000 of them developed type 2 diabetes and nearly 16,000 developed heart disease. The participants' answers to food-frequency questionnaires allowed the researchers to estimate their individual intake of phytosterols, as well as three individual phytosterols known as β-sitosterol, campesterol and stigmasterol. Those who ate the most consumed the most phytosterol had about four to five servings of vegetables, two to three servings of fruits, two servings of whole grains, and half a serving of nuts each day. This made them 9 percent less likely to develop heart disease and 8 percent less likely to develop type 2 diabetes compares to those in the bottom fifth percentage for phytosterol intake, the research showed. Looking at the individual phytosterols, similar associations were observed for β-sitosterol. But, the same was not true for campesterol or stigmasterol. In addition, the researchers analyzed blood samples, looking at the products of metabolism — also known as metabolites — from more than 11,000 people and other metabolic biomarkers in blood samples from over 40,000 participants. They found that phytosterol and β-sitosterol levels were tied to favorable metabolites and metabolic markers relevant to heart disease and diabetes. That signaled a possible reason for the association. 'Our clinical biomarker and metabolomic results suggest the involvement of insulin activity, inflammation and the metabolism of metabolites associated with type 2 diabetes and cardiovascular disease,' said Wang. 'This suggests that phytosterol might reduce risk by alleviating insulin resistance and inflammation.' In a group of just 465 participants, they examined the gut microbiome, or the trillions of microscopic organisms inside the intestines. They found several microbial species and related enzymes linked to higher intake of phytosterols that may affect the production of metabolites associated with a lower risk of diseases. 'We found that the gut microbiome might play a role in the beneficial associations. Some species, such as Faecalibacterium prausnitzii, carry enzymes that could help degrade phytosterol, potentially influencing host metabolism,' Wang said.
